Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings

被引:69
|
作者
Krawczyk, Noa [1 ]
Williams, Arthur Robin [2 ]
Saloner, Brendan [3 ]
Cerda, Magdalena [1 ]
机构
[1] NYU, Grossman Sch Med, Dept Populat Hlth, Room 4-12,180 Madison Ave, New York, NY 10003 USA
[2] Columbia Univ, New York State Psychiat Inst, Dept Psychiat, New York, NY 10027 USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
关键词
Medication treatment; Opioid use disorder; Retention; Discontinuation; Overdose; METHADONE-MAINTENANCE TREATMENT; BUPRENORPHINE TREATMENT; UNITED-STATES; RETENTION; DISCONTINUATION; DEPENDENCE; OUTCOMES; RELEASE; PROGRAM; METAANALYSIS;
D O I
10.1016/j.jsat.2021.108329
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Maintenance treatments with medications for opioid use disorder (MOUD) are highly effective at reducing overdose risk while patients remain in care. However, few patients initiate medication and retention remains a critical challenge across settings. Much remains to be learned about individual and structural factors that influence successful retention, especially among populations dispensed MOUD in outpatient settings. Methods: We examined individual and structural characteristics associated with MOUD treatment retention among a national sample of adults seeking MOUD treatment in outpatient substance use treatment settings using the 2017 Treatment Episode Dataset-Discharges (TEDS-D). The study assessed predictors of retention in MOUD using multivariate logistic regression and accelerated time failure models. Results: Of 130,300 episodes of MOUD treatment in outpatient settings, 36% involved a duration of care greater than six months. The strongest risk factors for treatment discontinuation by six months included being of younger age, ages 18-29 ((OR):0.52 [95%CI:0.50-0.54]) or 30-39 (OR:0.57 [95%CI:0.55-0.59); experiencing homelessness (OR: 0.70 [95%CI:0.66-0.73]); co-using methamphetamine (OR:0.48 [95%CI:0.45-0.51]); and being referred to treatment by a criminal justice source (OR:0.55 [95%CI:0.52-0.59) or by a school, employer, or community source (OR:0.71 [95%CI:0.66-0.76). Conclusions: Improving retention in treatment is a pivotal stage in the OUD cascade of care and is critical to reducing overdose deaths. Efforts should prioritize interventions to improve retention among patients who are both prescribed and dispended MOUD, especially youth, people experiencing homelessness, polysubstance users, and people referred to care by the justice system who have especially short stays in care.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Medication-Assisted Treatment for Adolescents in Specialty Treatment for Opioid Use Disorder
    Feder, Kenneth A.
    Krawczyk, Noa
    Saloner, Brendan
    [J]. JOURNAL OF ADOLESCENT HEALTH, 2017, 60 (06) : 747 - 750
  • [2] IMPLEMENTATION OF MEDICATION TREATMENT FOR OPIOID USE DISORDER IN CORRECTIONAL SETTINGS
    Bandara, Sachini
    Kennedy-Hendricks, Alene
    Merritt, Sydney
    Barry, Colleen
    Eisenberg, Matthew
    Rabideau, Brendan
    Saloner, Brendan
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (SUPPL 1) : S169 - S169
  • [3] Correlates of death during outpatient treatment for opioid use disorder: A national study
    Goldman, Jacqueline E.
    Samuels, Elizabeth A.
    Rich, Josiah D.
    Marshall, Brandon D. L.
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2020, 112 : 76 - 85
  • [4] Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016
    Askari, Melanie S.
    Martins, Silvia S.
    Mauro, Pia M.
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2020, 114
  • [5] Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings Harm Reduction in Outpatient Addiction Treatment
    Taylor, Jessica L.
    Johnson, Samantha
    Cruz, Ricardo
    Gray, Jessica R.
    Schiff, Davida
    Bagley, Sarah M.
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2021, 36 (12) : 3810 - 3819
  • [6] Medication Treatment of Opioid Use Disorder
    Bell, James
    Strang, John
    [J]. BIOLOGICAL PSYCHIATRY, 2020, 87 (01) : 82 - 88
  • [7] Clinical stakeholders' perceptions of patient engagement in outpatient medication treatment for opioid use disorder: A qualitative study
    Poulsen, Melissa N.
    Roe, Sophie A.
    Asdell, Patrick B.
    Rahm, Alanna Kulchak
    Berrettini, Wade
    [J]. JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 158
  • [8] Outpatient care for opioid use disorder among the commercially insured: Use of medication and psychosocial treatment
    Busch, Alisa B.
    Greenfield, Shelly F.
    Reif, Sharon
    Normand, Sharon-Lise T.
    Huskamp, Haiden A.
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2020, 115
  • [9] An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated
    Brezel, Emma R.
    Powell, Tia
    Fox, Aaron D.
    [J]. SUBSTANCE ABUSE, 2020, 41 (02) : 150 - 154
  • [10] Treatment of Opioid Use Disorder in Pediatric Medical Settings
    Sharon Levy
    Deepa Camenga
    [J]. Current Addiction Reports, 2019, 6 : 374 - 382